Table 5. Neutralization and... | American Society of Hematology

Table 5.

Neutralization and Immunoprecipitation Assays of Plasmas From 21 Autoantibody Inhibitors

Inhibitor	% Neutralization by FVIII Region			Epitopes of Major	Immunoprecipitation of
	A2	C2	LCh	Inhibitor(s)	A2	C2
				Domain(s)
EM	≥95	—	≤5	A2	+	+
JM^5-150	≥95	≤5	≤5	A2	+	−
NS	≥95	≤5	≤5	A2	+	+
MR	≤5	≥95	≥95	C2	+	+
MSI1801	≤5	≥95	≥74	C2	−	+
D	≤5	81	88	C2	+	+
SLC	≤5	70	≥50	C2	−	+
HR^5-150	≤10	≥95	≥95	C2^IS	−	+
LK^5-150	≤5	≥95	≥95	C2^IS	+	+
AA^5-150	≤10	79	87	C2^IS	+	+
UJ	≤10	74	84	C2^IS	+	+
DP	≤5	≥95	90	C2^IS	+	+
PF^5-150	≤5	91	93	C2	+	+
FM^5-150	81	19	11	A2, C2	+	+
WC^5-150	59	32	36	A2, C2^IS	+	+
F	≤5	65	96	C2, AR3-A3-C1	+	+
EH	≤5	82	99	C2, AR3-A3-C1^IS	+	+
SL^5-150	≤10	57	86	C2, AR3-A3-C1^IS	+	+
WT	≤5	48	86	C2, AR3-A3-C1	+	+
CHI^5-150	20	79	90	A2, C2, AR3-A3-C1^IS	+	+
SC^5-150	51	25	46	A2, C2, AR3-A3-C1	+	+

Inhibitor	% Neutralization by FVIII Region			Epitopes of Major	Immunoprecipitation of
	A2	C2	LCh	Inhibitor(s)	A2	C2
				Domain(s)
EM	≥95	—	≤5	A2	+	+
JM^5-150	≥95	≤5	≤5	A2	+	−
NS	≥95	≤5	≤5	A2	+	+
MR	≤5	≥95	≥95	C2	+	+
MSI1801	≤5	≥95	≥74	C2	−	+
D	≤5	81	88	C2	+	+
SLC	≤5	70	≥50	C2	−	+
HR^5-150	≤10	≥95	≥95	C2^IS	−	+
LK^5-150	≤5	≥95	≥95	C2^IS	+	+
AA^5-150	≤10	79	87	C2^IS	+	+
UJ	≤10	74	84	C2^IS	+	+
DP	≤5	≥95	90	C2^IS	+	+
PF^5-150	≤5	91	93	C2	+	+
FM^5-150	81	19	11	A2, C2	+	+
WC^5-150	59	32	36	A2, C2^IS	+	+
F	≤5	65	96	C2, AR3-A3-C1	+	+
EH	≤5	82	99	C2, AR3-A3-C1^IS	+	+
SL^5-150	≤10	57	86	C2, AR3-A3-C1^IS	+	+
WT	≤5	48	86	C2, AR3-A3-C1	+	+
CHI^5-150	20	79	90	A2, C2, AR3-A3-C1^IS	+	+
SC^5-150	51	25	46	A2, C2, AR3-A3-C1	+	+

Abbreviations and symbols are as described in Table 1. A neutralization assay of FM by peptide 355-362 was negative (≤5%). The average maximal neutralization by heavy chain plus LCh polypeptides was 93% ± 7.6% SD.

^IS Patients treated with immunosuppressants.

F5-150

Patients never treated with fVIII.

View Large

This Feature Is Available To Subscribers Only